Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology
- PMID: 28669492
- DOI: 10.1016/j.ophtha.2017.05.032
Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology
Abstract
Purpose: To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children.
Methods: Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist.
Results: Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5%, 0.1%, and 0.01%) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01%, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5%, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression.
Conclusions: Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Use of Orthokeratology for the Prevention of Myopic Progression in Children: A Report by the American Academy of Ophthalmology.Ophthalmology. 2019 Apr;126(4):623-636. doi: 10.1016/j.ophtha.2018.11.026. Epub 2018 Nov 23. Ophthalmology. 2019. PMID: 30476518 Review.
-
Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia.J Ocul Pharmacol Ther. 2015 Nov;31(9):541-5. doi: 10.1089/jop.2015.0043. Epub 2015 Jul 28. J Ocul Pharmacol Ther. 2015. PMID: 26218150
-
Interventions to retard myopia progression in children: an evidence-based update.Ophthalmology. 2002 Mar;109(3):415-21; discussion 422-4; quiz 425-6, 443. doi: 10.1016/s0161-6420(01)00972-1. Ophthalmology. 2002. PMID: 11874738 Review.
-
Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.JAMA. 2023 Feb 14;329(6):472-481. doi: 10.1001/jama.2022.24162. JAMA. 2023. PMID: 36786791 Free PMC article. Clinical Trial.
-
Prevention of myopia progression with 0.05% atropine solution.J Ocul Pharmacol Ther. 2006 Feb;22(1):41-6. doi: 10.1089/jop.2006.22.41. J Ocul Pharmacol Ther. 2006. PMID: 16503774
Cited by
-
Association Between Myopia and Pupil Diameter in Preschoolers: Evidence from a Machine Learning Approach Based on a Real-World Large-Scale Dataset.Ophthalmol Ther. 2024 Jul;13(7):2009-2022. doi: 10.1007/s40123-024-00972-5. Epub 2024 Jun 1. Ophthalmol Ther. 2024. PMID: 38822998 Free PMC article.
-
Effect of 0.01% atropine combined with orthokeratology lens on axial elongation: a 2-year randomized, double-masked, placebo-controlled, cross-over trial.Front Med (Lausanne). 2024 Apr 23;11:1358046. doi: 10.3389/fmed.2024.1358046. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38716420 Free PMC article.
-
Addressing Glaucoma in Myopic Eyes: Diagnostic and Surgical Challenges.Bioengineering (Basel). 2023 Oct 29;10(11):1260. doi: 10.3390/bioengineering10111260. Bioengineering (Basel). 2023. PMID: 38002384 Free PMC article. Review.
-
Efficacy and safety of atropine at different concentrations in prevention of myopia progression in Asian children: a systematic review and Meta-analysis of randomized clinical trials.Int J Ophthalmol. 2023 Aug 18;16(8):1326-1336. doi: 10.18240/ijo.2023.08.20. eCollection 2023. Int J Ophthalmol. 2023. PMID: 37602338 Free PMC article.
-
Optical Biometry Changes Throughout Childhood and Adolescence in Patients Wearing Ortho-K Lenses.Clin Ophthalmol. 2023 Jul 4;17:1919-1927. doi: 10.2147/OPTH.S413810. eCollection 2023. Clin Ophthalmol. 2023. PMID: 37425028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources